Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 200

1.
2.
3.

Extracellular matrix remodeling may predominate over hepatocyte injury in hepatocellular carcinoma development.

Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, Namisaki T, Yamazaki M, Tsujinoue H, Imazu H, Fukui H.

Oncol Rep. 2003 Jul-Aug;10(4):957-62.

PMID:
12792752
4.

Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet.

Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K.

Biochem Biophys Res Commun. 2004 Feb 27;315(1):187-95.

PMID:
15013444
5.
6.

Fibrosis accelerates the development of enzyme-altered lesions in the rat liver.

Sakaida I, Hironaka K, Uchida K, Suzuki C, Kayano K, Okita K.

Hepatology. 1998 Nov;28(5):1247-52.

PMID:
9794908
7.

Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats.

Shimizu I, Ma YR, Mizobuchi Y, Liu F, Miura T, Nakai Y, Yasuda M, Shiba M, Horie T, Amagaya S, Kawada N, Hori H, Ito S.

Hepatology. 1999 Jan;29(1):149-60.

PMID:
9862861
9.
10.

JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis1.

Yamamoto H, Kondo M, Nakamori S, Nagano H, Wakasa K, Sugita Y, Chang-De J, Kobayashi S, Damdinsuren B, Dono K, Umeshita K, Sekimoto M, Sakon M, Matsuura N, Monden M.

Gastroenterology. 2003 Aug;125(2):556-71.

PMID:
12891558
13.

Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats.

Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T, Imazu H, Yanase K, Kuriyama S, Fukui H.

J Hepatol. 2002 Jul;37(1):22-30.

PMID:
12076858
14.

Effects of Sho-saiko-to extract on liver fibrosis in relation to the changes in hydroxyproline and retinoid levels of the liver in rats.

Ono M, Miyamura M, Kyotani S, Saibara T, Ohnishi S, Nishioka Y.

J Pharm Pharmacol. 1999 Sep;51(9):1079-84.

PMID:
10528993
15.
16.

Effect of Sho-saiko-to extract on hepatic inflammation and fibrosis in dimethylnitrosamine induced liver injury rats.

Kusunose M, Qiu B, Cui T, Hamada A, Yoshioka S, Ono M, Miyamura M, Kyotani S, Nishioka Y.

Biol Pharm Bull. 2002 Nov;25(11):1417-21.

17.

The role of TGF-beta 1 and cytokines in the modulation of liver fibrosis by Sho-saiko-to in rat's bile duct ligated model.

Chen MH, Chen JC, Tsai CC, Wang WC, Chang DC, Tu DG, Hsieh HY.

J Ethnopharmacol. 2005 Feb 10;97(1):7-13. Epub 2004 Dec 10.

PMID:
15652268
18.

Sho-saiko-to: Japanese herbal medicine for protection against hepatic fibrosis and carcinoma.

Shimizu I.

J Gastroenterol Hepatol. 2000 Mar;15 Suppl:D84-90. Review.

PMID:
10759225
19.
20.

Inhibition by piroxicam of oxidative DNA damage, liver cirrhosis and development of enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats.

Denda A, Endoh T, Kitayama W, Tang Q, Noguchi O, Kobayashi Y, Akai H, Okajima E, Tsujiuchi T, Tsutsumi M, Nakae D, Konishi Y.

Carcinogenesis. 1997 Oct;18(10):1921-30.

PMID:
9364001

Supplemental Content

Support Center